Humana has added another 5% this week, and the Street is finally starting to move — though the targets are still lagging badly behind the tape.
The clearest story this week is the analyst pivot. Deutsche Bank's George Hill upgraded HUM to Buy this morning, lifting his target from $235 to $441 — a dramatic shift that signals at least one major firm now believes the post-earnings repricing has legs. Mizuho's Ann Hynes maintained Outperform and raised her target to $335 from $290, also filed today. These moves matter because just a week ago — as noted in the prior note — the mean analyst target of $243 sat roughly 17% below the stock price, a gap that made the rally look like it had run past the Street. That gap has narrowed, but the consensus picture remains fragmented: Morgan Stanley holds an Underweight at $217, while JP Morgan and Piper Sandler both sit at Neutral with targets in the $214–$254 range. The majority of the Street is not yet bought in.
The bull and bear cases remain sharply defined. Bulls point to the 500 basis-point improvement in Group Medicare Advantage margins and 16% revenue growth at CenterWell, and Deutsche Bank's upgrade today suggests at least one major desk is now prioritising the margin recovery over the macro headwinds. Bears counter with the $3.5 billion headwind from declining MA Star ratings — a drag worth roughly $22 in EPS for 2026 — and point to inadequate reimbursement rates as a structural concern that doesn't disappear with one quarter's beat. The P/E multiple has expanded by 7.6 points over the past month to 27.5x, and the price-to-book ratio has risen by 0.63 to 2.0x — a meaningful re-rating in a short period that leaves less room for disappointment.
Short positioning tells a cautious but not aggressive story. Short interest has climbed steadily through May, reaching 5.7% of the free float — up 5.7% on the week and back to levels last seen before the April earnings surge. That pace of rebuild is notable given how far the stock has run. Borrow conditions remain relaxed: cost to borrow is just 0.48%, and availability is extremely wide at over 1,470% of short interest, meaning there are roughly fifteen shares available to borrow for every one currently lent out. There is no squeeze pressure here. The ORTEX short score has drifted higher this week to 42.6 but remains in a moderate range — 36th percentile for the sector on short score rank — suggesting this is a stock being selectively re-shorted by traders fading the rally rather than a crowded short.
Options positioning has turned more defensive than at any point in recent weeks. The put/call ratio jumped to 0.93 on Tuesday, more than two standard deviations above its 20-day average of 0.85 — the highest single-day reading since late April. That spike followed a period of unusually calm options activity, making the shift more pronounced. It is worth noting that UNH and CVS — the two closest sector peers — each fell around 1–2% on the week, while ELV gained 2.3% in line with HUM. The managed-care sector broadly is moving, but HUM remains the outlier on the upside.
Pzena Investment Management added 1.4 million shares in the quarter ending March 31, lifting its stake to 4.6% of shares outstanding. Sessa Capital also added 1.4 million shares in the same period, building to 3.1%. Both moves would have been made at prices well below current levels — somewhere in the $175–$185 range based on the February/March insider activity — and represent significant unrealised gains for those holders. The positioning question heading into July 29 earnings is whether those holders and short sellers who have been rebuilding positions over the past two weeks can coexist without forcing a rapid move in either direction.
With Deutsche Bank's $441 target now the highest on the Street and the mean consensus still closer to $250, the next print on July 29 is less about whether the MA margin story is real and more about whether the pace of improvement can justify a stock that has risen 51% in a single month.
See the live data behind this article on ORTEX.
Open HUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
